Yakup Ergün

Survival Outcomes in Real-World Settings After Alternative Pembrolizumab Dosing for NCSLC

Yakup Ergün, Medical Oncologist at Bower Hospital, shared a post on X, about recent paper published in Lung Cancer:

Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective.

Authors: Geeske Grita, Esmée van Geffen, Ruben Malmberg, Roelof van Leeuwen, Stefan Böhringer, Hans JM Smith, Pepijn Brocken, Job FH Eijsink, Esther Dronkers, Pim Gal, Eva Jaarsma, Regine JHM van Drie-Pierik, Anne MP Eldering-Heldens, AN Machteld Wymenga, Peter GM Mol, Juliëtte Zwaveling, Doranne Hilarius.

Survival Outcomes in Real-World Settings After Alternative Pembrolizumab Dosing for NCSLC

”Real-world overall survival after alternative dosing for pembrolizumab in the treatment of NCSLC.

In this RWD involving 1996 patients, low-dose pembrolizumab significantly reduces costs without compromising efficacy.”

Source: Yakup Ergün/X

AN Machteld Wymenga Anne MP Eldering-Heldens Bower Hospital cancer cancer treatment Doranne Hilarius Esmée van Geffen Esther Dronkers Eva Jaarsma Geeske Grita Hans JM Smith Job FH Eijsink Juliëtte Zwaveling Lung cancer OncoDaily Oncology pembrolizumab Pepijn Brocken Peter GM Mol Pim Gal Regine JHM van Drie-Pierik Roelof van Leeuwen Ruben Malmberg Stefan Böhringer Yakup Ergün